Pharmaron

Allergan Biologics developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products.

Imago BioSciences is a clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives. Imago BioSciences was founded in 2012 and is based in Redwood City, California.

Absorption Systems develops and implements research tools that allow their customers to better predict human outcomes. They have locations in Exton, Pennsylvania, San Diego, California, and Panama City, Panama. They work with a wide variety of customers in the pharmaceutical and biotech industry, including small virtual pharma companies, large pharma companies with weekly programs, and specialty CROs looking for services that complement their own offerings. Their flexibility allows us to adapt to the needs of each customer. They believe that projects should be viewed as a collaboration, which allows us to work with you to design studies and develop custom models when necessary. This collaborative approach has resulted in the generation of several innovative models to aid in drug discovery and development, through working partnerships within the industry and with regulatory agencies.

Xceleron believes that AMS technology and our expertise can get life-changing products quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.

Quotient Bioresearch is a leading CRO, providing Radiochemistry, Drug Metabolism and E-fate solutions tailored, integrated.

Bridge Laboratories, Inc. operates as a preclinical contract research organization. Its drug development and preclinical services include short and long-term in vivo studies ranging from acute to carcinogenicity protocols; and species and routes of administration.